Katelyn Miller

#postdoc Opinions are solely my own.

[Katelyn Miller @mkatelyndyan]

1/n Excited to share the first, first author paper of my postdoc! Targeting of ACSS2 with a transition state mimetic to inhibit triple negative breast cancer growth. A thread. @Schuglab @TheWistar #ACSS2 #Acetate #Metabolism #CancerResearch

https://t.co/al6gMPLqFY

[Katelyn Miller @mkatelyndyan]

My last day in person @SchugLab. After over 4 years in #cancer #metabolism I will be moving to an industry position. Thanks for everything Zach!! Also Zach is hiring for a postdoc, reach out if you need any details and want to join an awesome group! #Acss2 #postdoc #postdocjobs

[Katelyn Miller @mkatelyndyan]

Check out our recent commentary exploring the possibilities of targeting acetate metabolism with small molecule inhibitors! @BrJCancer @SchugLab #acetate #metabolism #cancermetabolism

https://t.co/HD9uDmdoDb

[Katelyn Miller @mkatelyndyan]

So excited to become an ACS fellow! @AmericanCancer

[The Wistar Institute @TheWistar]

Thank you @AmericanCancer for awarding the Rena and Victor Damone Postdoctoral Fellowship in Cancer Research to Dr. Katelyn Miller from @TheWistar’s @SchugLab for her research on targeting the #Acetate #metabolism in #breastcancer. https://t.co/EbeBSFdpti

[Katelyn Miller @mkatelyndyan]

@SchugLab !

[PA Breast Cancer Coalition @PBCC]

🔬𝐘𝐨𝐮𝐫 𝐃𝐨𝐧𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐭 𝐖𝐨𝐫𝐤🧬

Meet 2021 PBCC Research Grant Winner Dr. Zachary Schug of @TheWistar!

Dr. Schug has identified a nutrient that feeds cancer cells & causes them to metastasize. He hopes to study that process & develop therapies for #breastcancer👇

[Katelyn Miller @mkatelyndyan]

@sattarsabdul @worxexell @washingtonpost https://t.co/AFKTQrHymK

[Katelyn Miller @mkatelyndyan]

Excited to be presenting at #VKSMetaImmune21 tomorrow. So far all of the talks have been great! Integrating metabolism and immunity, so much to learn.

[Jason Sheltzer @JSheltzer]

American Cancer Society CRISPR symposium this afternoon! RSVP with [email protected] for the Zoom link - all are welcome. Should be a great event!

[Katelyn Miller @mkatelyndyan]

So happy to have trained with @GlennRallPhD !!

[Fox Chase Cancer Center @FoxChaseCancer]

It's important to share factual info when it comes to the #COVID19 vaccine. Fox Chase's @GlennRallPhD and @templemedschool's Dr. Heather Clauss (@heathercmd2) share answers to some common questions about the #COVIDvaccine. Watch here: https://t.co/X7V8Ld61CN.

[Katelyn Miller @mkatelyndyan]

7/7 Short answer, ACSS1 can use either acetate or propionate, ACSS2 heavily favors acetate, and ACSS3 heavily favors propionate. Lastly, the ACSS2 inhibitors we tested were highly specific for ACSS2 over ACSS1 or ACSS3. Looking forward to pursuing our findings further!!

[Katelyn Miller @mkatelyndyan]

1/n Excited to share the first, first author paper of my postdoc! Targeting of ACSS2 with a transition state mimetic to inhibit triple negative breast cancer growth. A thread. @Schuglab @TheWistar #ACSS2 #Acetate #Metabolism #CancerResearch

https://t.co/al6gMPLqFY

[Katelyn Miller @mkatelyndyan]

6/n We also tested the ability of the other short chain acyl-CoA synthetase family members ACSS1 and ACSS3 to catalyze the conversion of acetate and propionate to their acyl-CoA products.

[Katelyn Miller @mkatelyndyan]

@TanentzapfLab Thats great and all until the editor then decides to get a 4th reviewer..

[Katelyn Miller @mkatelyndyan]

@DrDDOM I usually get them to spin without every closing the lids. Thats what I meant. Super neat overall though!

[Katelyn Miller @mkatelyndyan]

@DrDDOM General use. First thing I do with any minifuge is learn how to bypass the safety! 😁Saves me a few extra seconds.

[Katelyn Miller @mkatelyndyan]

@DrDDOM How quickly were you able to bypass the “safety” lid?

[Katelyn Miller @mkatelyndyan]

@JenKirkman Literally bought one Friday.